Brez internetne povezave — prikazana je shranjena različica strani.

AbbVie Inc

USUSD
← Na Filter Delnic

AbbVie Inc (XETRA:4AB) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 4. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O Podjetju

Spletna Stran
abbvie.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Sedež
North Chicago, United States
Izvršni Direktor
Robert A. Michael
Zaposleni
57 000
Ustanovljena
2012
Na Borzi od
17.05.2016 (XETRA:4AB)
Delnice v Obtoku
1.77 mrd. na dan 2026-07-27
1 Leto: +0.03% · 3 leta: +0.1% · 5 let: — (brez razcepov delnic)
DatumDelniceSprememba
27.07.20261.77 mrd.+0.02%brez bistvenih sprememb
28.04.20261.77 mrd.−0.08%brez bistvenih sprememb
10.02.20261.77 mrd.+0.04%brez bistvenih sprememb
27.10.20251.77 mrd.+0.05%brez bistvenih sprememb
29.07.20251.77 mrd.—brez bistvenih sprememb
30.04.20251.77 mrd.+0.06%brez bistvenih sprememb
31.01.20251.77 mrd.−0.1%odkup
28.10.20241.77 mrd.+0.05%brez bistvenih sprememb
29.07.20241.77 mrd.+0.03%brez bistvenih sprememb
25.04.20241.77 mrd.−0.03%brez bistvenih sprememb
31.01.20241.77 mrd.+0.05%brez bistvenih sprememb
27.10.20231.77 mrd.+0.03%brez bistvenih sprememb
31.07.20231.77 mrd.+0.04%brez bistvenih sprememb
25.04.20231.76 mrd.−0.3%odkup
31.01.20231.77 mrd.+0.05%brez bistvenih sprememb
Število delnic po poročilih podjetja. Razcep se prepozna po skoku števila za celo število krat.
Prosto Prenosljive Delnice
1.76 mrd.
Tržna Kapitalizacija
470.55 mrd. USD
Notranje Osebe
0.11%
Institucionalni Vlagatelji
77.37%
Panoga (SIC)
Pharmaceutical Preparations
Pravna Oblika
XTIQ
ISIN
US00287Y1091
LEI
FR5LCKFTG8054YNNRU85
P/E
80.6
Delež Izplačila
190%
FCF
18.2 mrd. USD
Izplačilo / FCF
66%
Dolg
70.8 mrd. USD
3.5 let FCF
Dividendni Staž
13 let
Dobički, FCF in izplačane dividende — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
NAV
−3.36 USD
Datum Bilance Stanja30.06.2026
Sredstva135 mrd. USD
− Obveznosti141 mrd. USD
= Skupni Kapital−5.89 mrd. USD
− Nekontrolni Deleži47.0 mio. USD
= NAV (lastniški delež delničarjev podjetja)−5.94 mrd. USD
− Dobro Ime35.5 mrd. USD
− Neopredmetna Sredstva49.1 mrd. USD
= Opredmetena NAV−90.6 mrd. USD
Delnice1 767 117 285
NAV na Delnico−3.36 USD
Otipljiv NAV na Delnico−51.27 USD
Kapital je negativen: obveznosti presegajo sredstva (pogosto zaradi velikih odkupov delnic). P/NAV ni izračunan.
Zgodovina NAV
Datum Bilance StanjaNAVNAV na Delnico
30.06.2026−5.94 mrd. USD−3.36 USD
31.03.2026−6.66 mrd. USD−3.77 USD
31.12.2025−3.27 mrd. USD−1.85 USD
30.09.2025−2.64 mrd. USD−1.49 USD
30.06.2025−183 mio. USD−0.10 USD
31.03.20251.42 mrd. USD0.80 USD
31.12.20243.33 mrd. USD1.88 USD
30.09.20246.03 mrd. USD3.41 USD
Opis

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

oglas

Borze in Oznake

BorzaOznakaValutaCenaVrsta
US USA StocksABBV glavnaUSD283.48 +3.32%navadne delnice
LSE London Stock Exchange0QCV IOBUSD275.5 +3.57%navadne delnice
MX Mexican Stock ExchangeABBV dodatnaMXN5 249 -0.28%navadne delnice
XETRA Xetra4AB dodatnaEUR245.7 +3.28%navadne delnice

Cena v 3 Mesecih

dan rasti dan padca ex-dividendni datum datum izplačilaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Dividende

Na leto, XETRA:4AB: 4.5646 EUR (3 izpl.)

AbbVie Inc (4AB) izplačuje dividende četrtletno. Na leto (12 mesecev do in vključno z najnovejšim napovedanim plačilom): 4.5646 EUR na delnico (plačila: 3). To je približno 1.86% trenutne cene delnice. Glede na zgodovino izplačil se naslednji datum ex-dividende pričakuje okoli 13.01.2027. Leta neprekinjenih dividend: 13.

Ex-DatumIzplačiloZnesek%VrstaOznaka
2026-07-15—1.5215 EUR0.7/2.8 %četrtletnoXETRA:4AB
2026-04-15—1.5215 EUR0.9/3.4 %četrtletnoXETRA:4AB
2026-01-16—1.5215 EUR0.8/3.1 %četrtletnoXETRA:4AB
2025-10-15—1.4424 EUR0.7/2.9 %četrtletnoXETRA:4AB
2025-07-15—1.4424 EUR0.9/3.5 %četrtletnoXETRA:4AB
2025-04-15—1.4424 EUR0.9/3.6 %četrtletnoXETRA:4AB
2025-01-15—1.4424 EUR0.8/3.3 %četrtletnoXETRA:4AB
2024-10-15—1.3632 EUR0.8/3.0 %četrtletnoXETRA:4AB
2024-07-15—1.3632 EUR0.9/3.4 %četrtletnoXETRA:4AB
2024-04-12—1.3632 EUR0.9/3.4 %četrtletnoXETRA:4AB
2024-01-12—1.3632 EUR0.9/3.5 %četrtletnoXETRA:4AB
2023-10-12—1.3017 EUR0.9/3.7 %četrtletnoXETRA:4AB
2023-07-13—1.3017 EUR1.1/4.2 %četrtletnoXETRA:4AB
2023-04-13—1.3017 EUR0.9/3.4 %četrtletnoXETRA:4AB
2023-01-12—1.3017 EUR0.9/3.5 %četrtletnoXETRA:4AB
2022-10-13—1.2401 EUR0.9/3.4 %četrtletnoXETRA:4AB
2022-07-14—1.2401 EUR0.8/2.5 %četrtletnoXETRA:4AB
2022-04-13—1.2401 EUR0.8/1.6 %četrtletnoXETRA:4AB
2022-01-13—1.2401 EUR1.0/1.0 %četrtletnoXETRA:4AB

Novice Ta Teden

Sporočila za javnost s spletne strani za vlagatelje podjetja, ki se dnevno posodabljajo. Povezave vodijo na spletno stran podjetja. Naslovi so v izvirnem jeziku, kot na spletni strani podjetja.

Največji Imetniki

ImetnikDeležDelniceDatum Poročila
BlackRock8.46%149.49 mio.2026-06-30
Vanguard Capital Managem…6.53%115.4 mio.2026-06-30
State Street Corporation4.67%82.6 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%56.09 mio.2026-06-30
Vanguard Portfolio Manag…2.74%48.48 mio.2026-06-30
JPMORGAN CHASE & CO2.71%47.86 mio.2026-06-30
Geode Capital Management…2.66%47 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%45.78 mio.2026-06-30
Morgan Stanley2.2%38.9 mio.2026-06-30
Capital Research Global…1.7%30.1 mio.2026-06-30
NORGES BANK1.45%25.55 mio.2026-06-30
iShares Trust-iShares Co…1.35%23.84 mio.2026-08-31
Fidelity Concord Street…1.29%22.85 mio.2026-07-31
SPDR S&P 500 ETF TRUST-S…1.22%21.61 mio.2026-08-31
Bank of America Corporat…1.2%21.24 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…0.95%16.82 mio.2026-06-30
SELECT SECTOR SPDR TRT-S…0.72%12.7 mio.2026-08-31
AMERICAN MUTUAL FUND0.63%11.15 mio.2026-07-31
Capital Income Builder0.57%10.06 mio.2026-07-31
VANGUARD SPECIALIZED FUN…0.57%10 mio.2026-07-31
GONZALEZ RICHARD A (Dire…≈0.02%386 4792025-03-31
SALEKI-GERHARDT AZITA (C…≈0.01%220 6822026-02-18
MICHAEL ROBERT A. (Chief…≈0.01%215 2602026-02-18
FREYMAN THOMAS C (Direct…≈0.01%135 7512026-05-08
STEWART JEFFREY RYAN (Of…≈0.01%108 3212026-02-18
DONOGHOE NICHOLAS (Offic…≈0%74 4302026-08-14
REENTS SCOTT T. (Chief F…≈0%60 4152026-02-18
THAKKAR ROOPAL (Officer)≈0%60 4132026-02-18
TILTON GLENN FLETCHER (D…≈0%51 9142025-05-09
RAPP EDWARD J (Director)≈0%45 9642026-05-08
The Vanguard Group———